CN101679358B - 作为p2y12拮抗剂的吡咯衍生物 - Google Patents

作为p2y12拮抗剂的吡咯衍生物 Download PDF

Info

Publication number
CN101679358B
CN101679358B CN2008800208356A CN200880020835A CN101679358B CN 101679358 B CN101679358 B CN 101679358B CN 2008800208356 A CN2008800208356 A CN 2008800208356A CN 200880020835 A CN200880020835 A CN 200880020835A CN 101679358 B CN101679358 B CN 101679358B
Authority
CN
China
Prior art keywords
phenyl
alkylene
alkyl
methyl
pyrrol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008800208356A
Other languages
English (en)
Chinese (zh)
Other versions
CN101679358A (zh
Inventor
O·克林勒
J·采奇
W·克泽齐迪斯基
T·魏斯
M·尤斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of CN101679358A publication Critical patent/CN101679358A/zh
Application granted granted Critical
Publication of CN101679358B publication Critical patent/CN101679358B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2008800208356A 2007-06-18 2008-06-04 作为p2y12拮抗剂的吡咯衍生物 Expired - Fee Related CN101679358B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07290755.3 2007-06-18
EP072907553 2007-06-18
EP07290755 2007-06-18
PCT/EP2008/004459 WO2008155022A1 (en) 2007-06-18 2008-06-04 Pyrrole derivatives as p2y12 antagonists

Publications (2)

Publication Number Publication Date
CN101679358A CN101679358A (zh) 2010-03-24
CN101679358B true CN101679358B (zh) 2013-10-30

Family

ID=39092503

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008800208356A Expired - Fee Related CN101679358B (zh) 2007-06-18 2008-06-04 作为p2y12拮抗剂的吡咯衍生物

Country Status (12)

Country Link
US (1) US7910576B2 (enExample)
EP (1) EP2167487B1 (enExample)
JP (1) JP5371969B2 (enExample)
KR (1) KR20100020478A (enExample)
CN (1) CN101679358B (enExample)
AU (1) AU2008266515B2 (enExample)
BR (1) BRPI0812912A2 (enExample)
CA (1) CA2690243A1 (enExample)
IL (1) IL202758A (enExample)
MX (1) MX2009013431A (enExample)
MY (1) MY148901A (enExample)
WO (1) WO2008155022A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2102195A1 (en) 2006-10-20 2009-09-23 Novartis AG Crystal modifications -3- (1h-ind0l-3-yl) -4- [2- (4-methyl-piperazin-1-yl) -quinazolin-4-yl]-pyrrole-2, 5-d ione
EP2750676B1 (en) 2011-08-30 2018-01-10 University of Utah Research Foundation Methods and compositions for treating nephrogenic diabetes insipidus
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
IL286902B2 (en) 2019-04-03 2025-03-01 Aligos Therapeutics Inc Pyrrole compounds
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3458515A (en) * 1966-07-21 1969-07-29 American Home Prod Piperazine substituted pyrroles
WO2001062255A1 (en) * 2000-02-22 2001-08-30 Bristol-Myers Squibb Company Antiviral azaindole derivatives
WO2005073203A1 (en) * 2004-01-16 2005-08-11 Bristol-Myers Squibb Company MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-κB ACTIVITY AND USE THEREOF
CN1778801A (zh) * 2004-11-22 2006-05-31 中国农业科学院兰州畜牧与兽药研究所 喹诺酮7－((4－((z)－2－(2－氨基－4－噻唑基)－2－甲氧亚胺乙酰基)－1－哌嗪基)化合物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
US6956040B2 (en) * 2001-07-16 2005-10-18 Ranbaxy Laboratories Limited Oxazolidinone piperazinyl derivatives as potential antimicrobials
CN1747732A (zh) 2002-12-11 2006-03-15 舍林股份公司 作为血小板腺苷二磷酸受体拮抗剂的2－氨基羰基喹啉化合物
WO2005009971A1 (ja) 2003-07-24 2005-02-03 Astellas Pharma Inc. キノロン誘導体又はその塩
WO2006073361A1 (en) * 2005-01-06 2006-07-13 Astrazeneca Ab Novel pyridine compounds
JP2008094720A (ja) 2005-01-20 2008-04-24 Astellas Pharma Inc キノロン誘導体のプロドラッグ又はその塩
EP1896483A2 (en) * 2005-03-28 2008-03-12 Pharmacia & Upjohn Company LLC 4-piperazinylthieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors
CA2627719C (en) * 2005-11-03 2016-07-12 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
WO2007103456A2 (en) * 2006-03-06 2007-09-13 Trimeris, Inc. Piperazine and piperidine biaryl derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3458515A (en) * 1966-07-21 1969-07-29 American Home Prod Piperazine substituted pyrroles
WO2001062255A1 (en) * 2000-02-22 2001-08-30 Bristol-Myers Squibb Company Antiviral azaindole derivatives
WO2005073203A1 (en) * 2004-01-16 2005-08-11 Bristol-Myers Squibb Company MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-κB ACTIVITY AND USE THEREOF
CN1778801A (zh) * 2004-11-22 2006-05-31 中国农业科学院兰州畜牧与兽药研究所 喹诺酮7－((4－((z)－2－(2－氨基－4－噻唑基)－2－甲氧亚胺乙酰基)－1－哌嗪基)化合物及其制备方法

Also Published As

Publication number Publication date
AU2008266515B2 (en) 2014-05-01
MY148901A (en) 2013-06-14
JP5371969B2 (ja) 2013-12-18
IL202758A (en) 2013-09-30
US7910576B2 (en) 2011-03-22
EP2167487A1 (en) 2010-03-31
AU2008266515A1 (en) 2008-12-24
US20100226918A1 (en) 2010-09-09
IL202758A0 (en) 2010-06-30
JP2010530380A (ja) 2010-09-09
MX2009013431A (es) 2010-01-15
EP2167487B1 (en) 2015-02-18
HK1142593A1 (en) 2010-12-10
BRPI0812912A2 (pt) 2014-12-09
CN101679358A (zh) 2010-03-24
KR20100020478A (ko) 2010-02-22
WO2008155022A1 (en) 2008-12-24
CA2690243A1 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
JP5560202B2 (ja) Ｐ２ｙ１２拮抗薬としてのピラゾール−カルボキサミド誘導体
JP5504171B2 (ja) Ｐ２ｙ１２アンタゴニストとしてのヘテロサイクリックピラゾール−カルボキサミド
JP4861306B2 (ja) Ｘａ因子阻害剤としてのピロール誘導体
US20110118262A1 (en) Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors
WO2017218633A1 (en) 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-one as apj agonists
JP2011511018A (ja) Ｐａｒ１阻害剤としてのｓｆ５誘導体、その製造、及び薬剤としての使用
KR20060136457A (ko) 인자 Ｘａ 억제제로서의 피롤-유도체
JP5371969B2 (ja) Ｐ２ｙ１２拮抗薬としてのピロール誘導体
CN102015675A (zh) 作为凝血因子Xa和凝血酶的抑制剂的氯噻吩-酰胺
EP1987021B1 (de) Substituierte prolinamide, deren herstellung und deren verwendung als arzneimittel
EP3077380B1 (en) Thienomethylpiperazine derivatives as inhibitors of soluble epoxide hydrolase
JP2006528941A (ja) 第Ｘａ因子阻害剤としてのトリアゾール誘導体
JP5422569B2 (ja) 凝固第Ｘａ因子及びトロンビンの阻害剤としてのクロロチオフェン−イソオキサゾール類
HK1142593B (en) Pyrrole derivatives as p2y12 antagonists
JPH08239380A (ja) １−オキソ−２−（フェニルスルホニルアミノ）ペンチルピペリジン誘導体、その製造及びその治療上の応用
UA82100C2 (uk) Похідні бензимідазолу як інгібітори фактора ха
RU2335494C2 (ru) Производные бициклических иминокислот в качестве ингибиторов матриксных металлопротеиназ
KR20060012636A (ko) 인자 Ｘａ 억제제로서의 아자인돌 유도체
KR101373533B1 (ko) 인자 Ｘａ 억제제로서의 헤테로아릴-카복실산(설파모일 알킬)아미드 유도체
HK1156607B (en) Chlorothiophene-amides as inhibitors of coagulation factors xa and thrombin

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1142593

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1142593

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20131030

Termination date: 20150604

EXPY Termination of patent right or utility model